Drug Profile
PMA 104R
Alternative Names: PMA-104RLatest Information Update: 06 Sep 2023
Price :
$50
*
At a glance
- Originator Pharmedartis
- Class Antineoplastics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Carcinoma; Pancreatic cancer; Prostate cancer; Solid tumours
Most Recent Events
- 06 Sep 2023 Discontinued - Preclinical for Carcinoma in Germany (unspecified route)
- 06 Sep 2023 Discontinued - Preclinical for Pancreatic cancer in Germany (unspecified route)
- 06 Sep 2023 Discontinued - Preclinical for Prostate cancer in Germany (unspecified route)